E-viri
PDF
Recenzirano
Odprti dostop
-
Jhaveri, Komal; Chandarlapaty, Sarat; Iyengar, Neil; Morris, Patrick G; Corben, Adriana D; Patil, Sujata; Akram, Muzaffar; Towers, Russell; Sakr, Rita A; King, Tari A; Norton, Larry; Rosen, Neal; Hudis, Clifford; Modi, Shanu
Clinical breast cancer, 08/2016, Letnik: 16, Številka: 4Journal Article
Micro-Abstract There is a lack of predictive biomarkers that can help determine a subset of patients who might most benefit from treatment with heat shock protein 90 (HSP90) inhibitors. Results from this retrospective tissue analysis from advanced solid tumor patients (most with breast cancer) who were treated with various HSP90 inhibitors suggest that HER2 might be the only effective biomarker of sensitivity to HSP90 inhibitors.
